Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats.
SB 209670 is a potent antagonist of the vasoconstrictor (ET(A)- and ET(B)-receptor-mediated) and vasodilator (ET(B)-receptor-mediated) effects of endothelin, whereas SB 234551 is relatively selective for the constrictor (ET(A)-receptor-mediated) effects. Since we had previously found SB 209670 exerted antihypertensive, vasodilator effects in conscious, heterozygous, transgenic ((mRen-2)27) (abbreviated to TG) rats, here we compared the two antagonists in that model, and assessed their chronic effects on responses to exogenous endothelin-1. We did this to test our global hypothesis, namely, that SB 209670, but not SB 234551, would cause inhibition of the depressor effects of exogenous endothelin-1 in vivo, and that this differential effect would be associated with a more marked antihypertensive action of SB 234551 in TG rats. SB 209670 and SB 234551 (infused for 50 h) exerted similar, sustained, antihypertensive effects in TG rats. The antihypertensive effects of the antagonists occurred at times when the pressor effects of exogenous endothelin-1 were not significantly inhibited. Furthermore, SB 234551 did not exert a greater antihypertensive effect than SB 209670 at a time (i.e., 2 - 4 h) when the depressor effects of endothelin-1 were abolished by the latter, but not by the former (although this differential action was lost after 24 h infusion). The results caused us to reject the hypothesis that selective antagonism of the vasoconstrictor effects of endothelin-1 would result in SB 234551 exerting a greater antihypertensive effect than SB 209670 in TG rats.
Gardiner
S M
SM
School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH.
March
J E
JE
Kemp
P A
PA
Bennett
T
T
D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D030801:Animals, Genetically Modified; D017704:Baroreflex / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002090:Butyrophenones / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D003243:Consciousness; D004149:Dioxoles / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000494:pharmacology*; D005260:Female; D005283:Fentanyl / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000235:genetics / Q000503:physiopathology*; D007189:Indans / Q000494:pharmacology; D008297:Male; D020926:Medetomidine / Q000494:pharmacology; D008723:Methohexital / Q000494:pharmacology; D051379:Mice; D008874:Midazolam / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000235:genetics; D013997:Time Factors
D000777:Anesthetics; D002090:Butyrophenones; D002317:Cardiovascular Agents; D004149:Dioxoles; D004338:Drug Combinations; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D007189:Indans; D011720:Pyrazoles; C113973:SB 234551; C087551:1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-; C001432:Hypnorm; D008723:Methohexital; D012083:Renin; D020926:Medetomidine; D008874:Midazolam; D005283:Fentanyl